The art of gene therapy for glioma: a review of the challenging road to the bedside
- Correspondence to Dr Maciej S Lesniak, The Brain Tumour Center, The University of Chicago, 5841 South Maryland Ave, MC 3026, Chicago, IL 60637, USA;
Contributors AT wrote and organised the manuscript. AA summarised the data on current gene therapy trials. K-SM provided an overview on current challenges. MSL read, reviewed, funded and approved the final review for submission.
- Received 10 April 2012
- Revised 16 July 2012
- Accepted 23 July 2012
- Published Online First 19 September 2012
Glioblastoma multiforme (GBM) is a highly invasive brain tumour that is unvaryingly fatal in humans despite even aggressive therapeutic approaches such as surgical resection followed by chemotherapy and radiotherapy. Unconventional treatment options such as gene therapy provide an intriguing option for curbing glioma related deaths. To date, gene therapy has yielded encouraging results in preclinical animal models as well as promising safety profiles in phase I clinical trials, but has failed to demonstrate significant therapeutic efficacy in phase III clinical trials. The most widely studied antiglioma gene therapy strategies are suicide gene therapy, genetic immunotherapy and oncolytic virotherapy, and we have attributed the challenging transition of these modalities into the clinic to four major roadblocks: (1) anatomical features of the central nervous system, (2) the host immune system, (3) heterogeneity and invasiveness of GBM and (4) limitations in current GBM animal models. In this review, we discuss possible ways to jump these hurdles and develop new gene therapies that may be used alone or in synergy with other modalities to provide a powerful treatment option for patients with GBM.
- Glioblastoma multiforme (GBM)
- gene therapy
- clinical trial
- molecular biology
Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumour in adults.1 Today, the current standard of care consists of surgical resection followed by radiotherapy and chemotherapy.2 However, the effectiveness of surgical resection is often compromised due to the lack of a defined tumour margin and a tumour burden located at a close proximity to vital anatomical structures in the brain. Moreover, due to the limitations associated with current standard therapeutic options as well as the presence of a chemo-resistant and radio-resistant glioma stem cell (GSC) population, which play a major role in initiating clinical relapse,3 the median survival time for patients diagnosed with GBM is a meagre ∼12–18 months with only ∼3% of patients surviving longer than 5 years.4 ,5 These statistics highlight the urgency of developing novel and effective therapeutic strategies against this devastating and uniformly fatal disease. As such, glioma has attracted a large amount of research attention as a target for gene therapy. ‘Gene therapy’ as related to brain tumours can be defined as the targeted transfer of genetic material into tumour cells for therapeutic purposes6 and has the ability to target invasive tumour cells that are resistant to conventional therapy and give rise to recurrent disease. Although gene therapy has shown promise in preclinical applications, it has not met clinical expectations due to various impediments related to the nature of the type of tumour and its location. The obstructions of gene therapy include: the anatomical barriers and physiological aspects of the brain that decrease transduction efficiency, tumour heterogeneity and invasiveness that challenge vector targeting and delivery,6 ,7 as well as a lack of a satisfactory preclinical model to study glioma. Here, we review relevant gene therapy approaches for the treatment of glioma and discuss the pertinent shortcomings, modifications and future directions in the field.
Gene therapy strategies for glioma
In the last decade, efforts to develop more effective and innovative gene therapy to target GBM have led to the preclinical characterisation of many promising gene therapy approaches. Many of these methods demonstrate therapeutic efficacy against glioma xenografts in an animal model and have been tested in clinical trials. Retroviral and adenoviral vectors have been the most widely used vectors for delivery of antiglioma therapeutic genes.8 According to the Journal of Gene Medicine, replication-defective adenoviruses represent ∼23% (n=424) and replication-deficient retroviruses ∼20% (n=365) of all gene therapy clinical trials worldwide as of January 2012. In this section, we outline the most widely evaluated antiglioma gene therapy strategies which are discussed in figure 1.
Suicide gene therapy
The most commonly used gene therapy approach against GBM in the preclinical setting as well as in clinical trials is the enzyme-prodrug suicide gene therapy system. In this approach, viral vectors or cell carriers are genetically modified to express genes for an enzyme that converts an inactive prodrug, when administered systemically into toxic metabolites at the tumour sites, resulting in tumour cell killing. Such targeted cytotoxic gene delivery approaches are designed to achieve highly selective tumour cell destruction while sparing normal central nervous system (CNS) tissue from toxicity. A large number of enzyme-prodrug systems have been evaluated in 17 different clinical trials ranging from phase I to phase III in the USA and Europe. In all 17 trials, adenoviral, retroviral or non-viral vector based delivery methods were used and modest to no increase in median survival was demonstrated (figure 2).33 ,34 Here, we briefly discuss some of the most commonly used suicide gene therapy systems against GBM.
Herpes simplex type 1 thymidine kinase (HSV-tk) is the most extensively investigated suicide gene therapy system against GBM. HSV-tk converts the inactive prodrug ganciclovir (GCV) into a toxic metabolite called GCV-triphosphate.35 Induction of the ‘bystander effect’ is thought to be one advantage of this therapy,36 which can be observed when the toxic metabolite converted by HSV-tk is lethal to tumour cells at distant sites that were not originally transduced with the therapeutic gene. In a xenograft glioma model, significant therapeutic efficacy has been observed when only ∼10% of total tumour cells in the disease burden are transduced with HSV-tk.17 ,37 In the clinic, successful delivery of the HSV-tk system into the tumour cavity has been achieved by replication-defective retrovirus (RV), adenovirus (Adv), cell carrier and reovirus packing cells. One of the largest phase III randomised clinical trials was conducted by Rainov where retroviral packing cells were used to deliver HSV-tk in the tumour bed of patients with glioma. This study recruited 248 total patients with newly diagnosed and previously untreated GBM who were treated with standard chemotherapy and radiotherapy (n=124) or standard therapy in combination with adjuvant retrovirus-mediated HSV-tk/GCV gene therapy (n=124).10 Patients received a mean volume of 9.1 ml of retroviral producing cells into the margins of the tumour cavity at a concentration of 108 cells/ml during the craniotomy. Even though the clinical trial proved that adjuvant gene therapy was safe, patient median survival was 365 days versus 354 days and the 12-month survival rates were 50% versus 55% in the gene therapy and control groups, respectively. These data showed no significant therapeutic benefit between both groups.10 Sandmair et al reported a phase I clinical trial where 21 primary or recurrent GBM patients were injected with RV-mediated HSV-tk/GCV (n=7) or replication-defective adenovirus carrying HSV-tk/GCV (n=7) intraoperatively in the margins of the tumour cavity.17 In this clinical trial, the mean survival of the group that received Adv-mediated HSV-tk/GCV was significantly higher (15 months, p<0.012) as compared with the group that was administered RV-mediated HSV-tk/GCV injection (7.4 months), indicating that the adenoviral vector may be better suited for antiglioma gene delivery. The HSV-tk system has also been shown to enhance sensitivity to conventional chemotherapy and radiotherapy, which opens the possibility of combining such an approach with the standard of care for GBM patients.38 ,39 Chiocca et al recently reported a phase IB clinical trial with 13 newly diagnosed GBM patients and observed that Adv-mediated HSV-tk/valacyclovir therapy in combination with conventional surgery and chemotherapy-radiotherapy can be clinically safe with no dose-limiting or significant added toxicity.40 The study also shed light on possible clinical efficacy in patients with an unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter with one patient living up to 46.4 months. A phase II study is currently ongoing to further evaluate survival and MGMT independence trends.40 Furthermore, it has been observed that combining HSV-tk with pharmacological drugs can alter the pharmacokinetics of the administered prodrugs, and has also been shown to increase therapeutic efficacy when used in conjunction with conventional therapy. One study showed that scopadulciol enhanced prodrug activity through a HSV-tk specific mechanism and increased tumour cell killing through the bystander effect of acyclovir and GCV prodrugs.41
The cytosine deaminase/5-fluorocytosine (CD/5-FC) gene therapy system has also been extensively investigated in the preclinical setting.42 ,43 This system is also capable of inducing a strong bystander effect; significant therapeutic efficacy has been observed in a xenograft tumour model when only 2%–4% of tumour cells are transduced.44 A second generation non-lytic retroviral replicating vector (Toca 511) has demonstrated that stable delivery of CD resulted in long-term survival in two different immunocompetent brain tumour models.45 Toca 511 is currently under phase I–II clinical investigation in combination with 5-FC in patients with recurrent high-grade glioma (NCT01156584). The CD/5-FC system has also been reported to enhance conventional radiotherapy against glioma in an animal model,46 and a fusion gene of CD used in conjunction with HSV-tk has shown to provide an increased antiglioma effect when compared with each individual gene used alone.47 ,48
Taken together, the antiglioma gene therapy approach using suicide genes is safe in treating patients with GBM, but has failed to achieve a consistent therapeutic benefit. These results can be attributed to limited spatial distribution of the viral vector, poor gene transfer efficiency into tumour cells and the inability to target disseminated tumour burden by the currently available gene transfer vectors. Moreover, with the exception of the Rainov trial,10 most of the early clinical trials treated a small number of patients, sometimes even without a control group. Therefore, it has been difficult to analyse whether these trials provided therapeutic efficacy in treated patients. Further optimisation of vectors used to deliver suicide gene therapy is essential for the improvement of clinical effectiveness. For the majority of antiglioma suicide gene therapy protocols, the short-term expression of therapeutic transgenes is sufficient to achieve tumour cell death. However, the restricted intratumoural distribution of the therapeutic payload still remains an issue for achieving optimal clinical efficacy. Greater viral vector stability as well as prolonged therapeutic transgene expression might result in more successful treatment of GBM. Thus, with use of adenovirus with superior glioma cell transduction capacity,17 and gutless adenovirus with reduced immunogenicity,49 conditionally replicating viral vectors might allow us to successfully translate antiglioma suicide gene therapy into the clinic because of their ability to amplify therapeutic transgenes via tumour-selective replication.
Oncolytic viral therapy
In order to address the issue surrounding the transduction efficiency of gene therapy vectors, researchers have engineered tumour-selective and conditionally replicating viral vectors referred to as oncolytic virus (OVs). OVs act by selective self-replication in tumour cells that leads to tumour cell lysis, as well as by amplifying therapeutic genes at tumour sites. It is evident from the current literature that tumour transduction efficiency is higher with replication competent viruses than with replication-deficient viruses, which highlights the potential of OVs as therapeutic gene delivery vehicles for anticancer gene therapy. Oncolytic herpes simplex virus (oHSV), conditionally replicating adenovirus (CRAd), reovirus, poliovirus, Newcastle disease virus and measles virus have all been evaluated or are currently being applied in antiglioma clinical trials (figure 2). Here, we describe some of the most commonly used antiglioma OV systems.
Oncolytic herpes simplex virus
oHSV was among the first OVs to be safely administered to patients with recurrent malignant glioma.50 Because HSV is a human pathogen with neurotropic properties, a critical issue in designing oHSVs is to provide tumour selectivity with an adequate safety profile. Since the first reported clinical trials using oHSV for the treatment of glioma in the late 1990s,51 at least eight different HSV-1 genes, including TK (UL23), ICP6 (UL39), γ34.5 and Us3, have been deleted/mutated to reduce neurovirulence and induce tumour selectivity.52 The most widely tested OV in clinical trials for antiglioma therapeutics is the oHSV vector G207, which is a genetically engineered HSV-1 vector that has a deleted γ34.5 gene at both alleles and a lacZ gene insertion that blocks the expression of the UL39 gene.53 Heretofore, three phase II and three phase I clinical trials have been conducted using the oHSV vector. Crusade Laboratories in Glasgow, Scotland, has begun a phase III clinical trial in Europe using HSV1716, an oHSV derived from the wild-type strain of ‘F’ containing attenuating mutation in both copies of the γ134.5 gene.53 In a recently reported phase IB clinical trial, six patients with resectable GBM received two injections of G207 during presurgery and postsurgery. Viral replication was observed but with limited evidence of antitumour activity.23 Results from early clinical trials have demonstrated high safety profiles of multiple oHSV vectors with no evidence of encephalitis but with limited therapeutic efficacy.54 Second generation oHSV vectors are currently under preclinical development where researchers have implemented various strategies to enhance oncolytic activity. Such strategies include those with a single copy of the γ34.5 gene reintroduced back into the vector that are genetically engineered to encode for therapeutic transgenes such as TNFα, vascular endothelial growth factor (VEGF) specific shRNA and the immunostimulatory gene interleukin (IL)-4.55–58 Others include surface retargeted HSVs that target glioma cells overexpressing human epidermal growth factor 259 and transcriptional targeting oHSVs that use tumour-selective promoters such as the HIF-responsive promoter.60 Development of new oHSVs provides optimism for the future.
Conditionally replicating adenovirus
CRAds have also been extensively evaluated in both preclinical and clinical settings for antiglioma therapeutics, with ONYX-015 and Ad5-Delta24 being the most widely studied. These CRAds have been adapted to replicate and lyse tumour cells in different ways: ONYX-015 has a deletion in the E1B gene that permits its replication in tumours with a defective p53 pathway, while Ad5-Delta24 relies on a deletion in the retinoblastoma binding region of the EIA protein allowing the vector to replicate in GBM cells that have a defective retinoblastoma function.61 A phase I clinical trial conducted by Chiocca and colleagues show that ONYX-015 is safe to administer into the tumour bed cavity postsurgical resection.32 A phase I clinical trial is currently underway evaluating Ad5-Delta24 (NCT00805376). Our group is currently conducting a US Food and Drug Administration (FDA) guided preclinical study evaluating the CRAd-Survivin-pk7 vector, which contains a tumour specific survivin promoter that drives adenovirus E1A replication and an inserted pk7 fibre region that has a high affinity to heparin sulphate proteoglycans, which confers tumour-selective replication.62–64 One important advantage of CRAd viruses is they are naturally non-neurotropic and thus may possess an enhanced safety profile over the oHSV vector.
Oncolytic measles and reovirus vectors
Oncolytic measles virus and reovirus vectors are currently under preclinical evaluation for GBM virotherapy. Tumour specific reovirus replication is dependent on hyperactive RAS signalling and has shown efficacy against GBM in an orthotropic animal model.65 In a phase I clinical trial, reovirus was injected directly into the tumour of patients with glioma, and no participants showed any signs of clinical encephalitis.31 Strains of the attenuated measles virus derived from the Edmonston vaccine lineage (MV-Edm) are also under preclinical development and have yielded positive results.66 A phase I clinical trial for recurrent GBM patients using MV-CEA, a MV-Edm vector expressing the soluble peptide marker, carcinoembryonic antigen, is currently underway (NCT00390299).67 Although conditionally replicating viruses represent a major advantage over non-replicative viruses in terms of transduction efficiency, the host antivector immune response remains as the major obstacle for the translation of OVs into the clinic.
Immunomodulatory gene therapy
The objective of antiglioma immunomodulatory gene therapy is to induce or augment the T cell-mediated immune response against GBM. During tumourigenesis, glioma cells evolve to evade the host immune system. Moreover, the distinct immune privileged nature of the CNS also poses issues for generating effective antiglioma immune responses.68 Nevertheless, preclinical experimental evidence has demonstrated the feasibility of inducing immune responses against glioma cells as well as chemo-resistant and radio-resistant GSCs, which has laid the foundation for formulating antiglioma gene therapy based on immunomodulation. Such strategies include cytokine-mediated gene therapy, immune cell recruitment strategies and application of cell carriers expressing immunomodulatory genes.
Cytokine-mediated gene therapy
The rationale for cytokine gene therapy is that tumour-selective gene transfer and in situ expression of various immunostimulatory genes such as IL-2, -12, -4, interferon (IFN)-γ and IFN-β may induce potent immune responses restricted towards antigens specific to glioma cells, but not to normal brain tissue.69–74 Moreover, cytokine-mediated gene therapy compared with systemic administration of suicide gene therapy and OV gene therapy may allow us to achieve higher local concentrations, longer therapeutic gene persistence and reduce systemic toxicity. Type 1 interferon genes including IFN-γ, IFN-β and IFN-ω are primarily produced by specialised antigen presenting cells such as dendritic cells (DCs) postviral infection and have been shown to elicit robust antitumour effects.75 Among the IFN genes, the IFN-β gene has direct antiproliferative effects and has been the most extensively evaluated cytokine for anticancer gene therapeutics. A two stage phase I clinical trial in which the initial treatment of five patients with GBM comprised of tumour resection was followed by injection of cationic liposomes with the human IFN-β gene into the margin of the resection cavity reported minimal clinical toxicity with 50% reduction of tumour size in two patients.76 Another dose-escalating phase I clinical trial of stereotactic injection of an adenovirus vector expressing the IFN-β gene in 11 patients with GBM recently demonstrated safety as well as possible therapeutic effects due to an increased level of apoptosis in glioma cells.77
Immune cell recruitment strategies
In the preclinical setting, Castro and her colleagues have used the Ad-Fms-like thyrosine kinase 3 ligand to recruit antigen presenting cells such as DCs into the brain tumour mass. Their strategy used DC recruitment combined with suicide gene therapy by simultaneously administrating a second adenovirus vector with the TK gene. In this approach, dying tumour cells release endogenous tumour associated antigen as well as the high mobility group box 1 protein that acts as an agonist to toll-like receptor 2 leading to DC recruitment and an antitumour immune response.78 ,79 This gene therapy approach has demonstrated tumour regression and long-term survival through its ability to induce an antiglioma immune response and immunological memory in several transplantable, orthotropic syngeneic models of GBM. In 2011, a phase I clinical trial was launched using this genetic immunotherapy approach.78
Cell carriers expressing immunomodulatory genes for antiglioma gene therapy
Stem cells or progenitor cells (SCs) have been evaluated extensively as therapeutic vehicles for antiglioma therapy due to their inherent tumour tropic properties. In the context of glioma, three types of SCs have been explored for their therapeutic use and are currently in preclinical development: neural, embryonic and mesenchymal. Embryonic stem cells have been modified to express and deliver mda-7/IL-24 and cause apoptosis in malignant glioma cells.80 Data also show similar apoptotic effects of embryonic stem cell-derived astrocyte-mediated delivery of TRAIL.81 Mesenchymal stem cells have been used to deliver a plethora of therapeutics to glioma including prodrugs, virus, cytokines and antibodies. One specific application is the genetic modification of human mesenchymal stem cells to express a single-chain antibody on their surface against the tumour specific antigen EGFRvIII. EGFRvIII was selected based on data showing that about ∼20%–30% of human GBM express this genetic alteration.82 In an intracranial glioma xenograft model of U87-EGFRvIII, animals injected with human mesenchymal stem cells expressing the single-chain antibody against EGFRvIII showed a significant survival advantage when compared with mock animals.83
Synthetic vectors such as nanoparticles
Nanoparticles have been studied as a method to intravenously deliver vectors that can cross the blood–brain barrier. This gene therapy modality is based on coupling genetic material to nanoparticles or microparticles, and delivering genes to a targeted site by way of their size, charge, as well as high surface to volume ratio that provides a powerful force for diffusion.84 ,85 Various genetic materials such as DNA plasmids, protein, RNA and siRNA have been conjugated onto or encapsulated inside nanoparticles to be delivered to tumour cells.85–87 Liposomes, due to their organic makeup, are the most widely investigated nanoparticles, and have been used to form artificial vesicles that encapsulate and deliver therapeutic agents such as RNA interference and small interfering RNA (siRNA). RNA interference has been used to silence specific messenger RNA and have led to the development of drugs against specific disease targets. Synthetic siRNAs have been shown to silence genes in vivo that are important for the pathogenesis of GBM.86 Therapeutics using siRNA represent a powerful tool for precise targeting of novel genes and have led to five different clinical trials that are currently ongoing.88
Challenges in developing effective antiglioma gene therapeutics
Each described strategy above has its own distinct advantages and disadvantages. Despite encouraging results in preclinical animal models and established safety profiles in phase I clinical trials, none of the gene therapies have demonstrated significant benefits in phase II and III clinical trials. The barriers limiting the efficient transition of gene therapy into the clinic include: anatomical barriers of the CNS that decrease the spatial distribution of the administered therapy, GBM heterogeneity and their invasiveness, cancer SCs, immunogenicity and limitations of established preclinical GBM models. In the following section, we discuss the various roadblocks of translation of antiglioma therapy from a preclinical setting to the clinic, and how the field of gene therapy has attempted to address them (table 1).
Limited spatial distribution of the therapeutic payload
One of major hurdles for achieving clinically relevant therapeutic efficacy by antiglioma gene therapeutic approaches is the limited tissue penetration and spatial distribution of the therapeutic payload in GBM tissue. To achieve clinically relevant therapeutic efficacy, any given anticancer therapy must effectively access the tumour site and destroy as many tumour cells as possible without affecting the surrounding healthy tissue. Physiologically, the CNS is protected by a unique anatomical barrier, the blood–brain barrier, which has been considered the major impediment to any systemic treatment of CNS diseases including glioma.97 Thus, most antiglioma gene therapeutic approaches are applied during craniotomy directly in the tumour bed or into the margins of the tumour cavity itself. Despite direct delivery, the transduction efficiency of glioma cells with the currently available viral and non-viral vectors remains poor. One reason contributing to the poor transduction efficiency is because only a small percentage of primary GBM cells express the cognate receptor for the viral vector that allow them to enter into the target tumour cells efficiently. For example, Ad5-based gene therapy for malignant glioma is limited due to the poor expression of the adenovirus entry receptor CAR on primary GBM.98 To overcome this problem, researchers have developed retargeted gene therapy strategies, which use receptors that are only expressed in glioma cells but not in normal neural tissue. Our laboratory has been using a CRAd with a fibre modification containing an inserted polylysine (pk7) motif that binds with a high affinity to heparin sulphate proteoglycans which has shown to confer glioma-selective internalisation. Another major limitation of gene therapy vectors is poor tissue penetration of the therapeutic virus after injection into glioma tissue. A clinical study demonstrated that the distribution of the viral vector was limited to an average range of 5 mm from the needle track.21 Researchers have been exploring a new delivery method known as convection-enhanced delivery (CED),99 which relies on continuous infusion of drugs and virus via intracranial catheters, enabling convective distribution of high virus/drug concentrations over large volumes of the targeted tissue.100 CED has been applied in a glioma clinical trial to administer large molecules, including immunotoxins,101 as well as to achieve enhanced transduction efficiency of the viral vector in a glioma xenograft model.102 These studies have shown that CED has the potential to improve the therapeutic efficacy of antiglioma gene therapy, but the success of this approach remains to be resolved. Furthermore, in the majority of antiglioma gene therapy clinical trials viral vectors were administered into the resection cavity or remaining tumour bed by a single injection, through a catheter or by multiple injections of a rather small volume of vector suspensions.18 ,20 ,21 Such injection protocols can be technically demanding, requiring precise estimation of the correct depth of the injection with respect to the extent of parenchyma-invading tumour cells. The accuracy and targeting capacity of therapeutic payload delivery protocols can be significantly improved if such injections are carried out with the help of robotic technology and guided by advanced imaging systems.
The host immune system and targeting the heterogenic and invasive properties of GBM
In theory, OVs should provide a solution for poor gene transfer efficiency as progeny released from the initial infected tumour cells should laterally spread to the tumour burden and amplify OV killing effects. However, results from early clinical trials using antiglioma OVs showed limited success due to the inability of currently available OVs to target disseminated glioma burdens as well as the host immune response interfering with viral vectors. The use of SCs has recently received a great deal of attention as possible cell carriers for targeted antiglioma therapy. In the last decade, many in vitro and in vivo studies demonstrated that SCs have unique inherent properties to migrate throughout the brain, target and home to metastatic invasive solid tumours, including gliomas.89 ,103 ,104 Aboody and colleagues have used prodrug systems to modify HB1.F3 neural SC (NSC) lines and were able to show a 70%–80% decrease in tumour volume of mice bearing orthotopic gliomas or intracranial melanoma.90 Based on the encouraging preclinical results, the FDA recently approved Aboody and colleagues to conduct the first clinical study of genetically modified neural SCs (HB1.F3-CD) for patients with recurrent high-grade glioma. This clinical trial began recruiting with the goal of enrolling 12–20 patients. Similarly, our lab has extensively investigated the possibility of using the inherent tumour tropic properties of NSCs to deliver glioma restricted oncolytic adenovirus selectively to disseminated tumour burdens. Our recent data indicates that distant delivery of NSCs loaded with oncolytic adenovirus significantly prolonged survival of animals in several orthotopic murine models of human glioblastoma when compared with mice treated with virus alone.63 ,64 We proved that the increased survival was due to amplified therapeutic virus at distant tumour sites in the presence of NSCs. Also, we have reported that a bone marrow mesenchymal SC carrier was able to protect the oncolytic viral therapeutic payload from the host immune system in a cotton rat model.105 There is also an abundance of preclinical data that suggest that in vivo transplanted NSCs can act as an immunosuppressant.106 It has been shown that NSCs lack the expression of major histocompatibility complex class II and express low levels of the co-stimulatory molecules CD80 and CD86 which provide them with protection from immune-mediated killing.94 NSCs have also been shown to express immunosuppressive cytokines such as IL-10 in the context of OV infection/loading.64 In the future, it will be crucial to gain a better understanding of the molecular mechanism underlying the tumour tropic properties of NSCs in order to increase their migratory capacity and improve the efficacy of this gene therapy system. Recent advancements in molecular imaging protocols using PET and/or MRI are providing us with the capacity to study SC migration in a non-invasive longitudinal manner, and may allow us to precisely delineate the mechanism of tumour tropism. Our lab has used ferumoxides-protamine sulphate labelled NSCs to visually track the migration of NSCs towards human glioma in an orthotropic mouse model. Information gathered from this technique may provide us with the insight to increase the migration of NSCs towards glioma in the future.
Another inherent characteristic of GBM is its heterogeneous makeup that exists due to the diverse genetic and epigenetic changes that accumulate in the pathogenesis of the different tissue subtypes found in GBM. This tumour property makes it exceptionally difficult to select one appropriate therapeutic approach against all tissue types in GBM.107 The use of drugs in combination with viral vectors has been applied to target multiple tumour cell types or tumour pathways to achieve a synergistic outcome. Bevacizumab (BEV) or Avastin, an antiangiogenic monoclonal antibody against VEGF, has been approved by the FDA for the treatment of GBM but has yielded no survival benefits in humans. Results of a study conducted by Zhang et al have shown that a local injection of G47Δ-mAngio, an HSV-derived OV expressing angiostatin, in conjunction with systemic administration of BEV increases virus spread throughout the brain, tumour killing and angiostatin inhibition of VEGF expression. Furthermore, this therapy synergises BEVs inhibitory activity of invasion markers such as matrix metalloproteinases-2 (MMP-2), MMP-9 and collagen. This adjunct therapy has led to increased survival in an intracranial mouse model of human glioma (U87) through increasing antiangiogenesis and reducing the invasiveness of GBM.108 Researchers are also using multiple viral vectors to target GBM heterogeneity and achieve therapeutic viral synergy. A current example of such is combining the vesicular stomatitis virus (VSV) with vaccinia virus (VV). VSV and VV were shown to enhance viral replication and infiltration throughout tumour cells of one another. Boeuf et al observed a 10- to 10 000-fold increase in VSV titres following co-infection of tumour samples with VV in 33 out of 44 tumour samples.109
Other approaches that target GBM heterogeneity focus on targeting cells that make it uniquely invasive and resistant to conventional cancer therapies, when compared with other human cancers. Research has attributed GBM's resistance to treatment and high rate of recurrence to a small subpopulation of cells called GSCs. GSCs have unique phenotypic properties which include relative quiescents as well as an ability to differentiate, self-renew, and resist chemotherapy and radiotherapy.110 Since a majority of investigated gene therapies focus on targeting properties retained in the main tumour bulk (ie, rapidly dividing cells) and not specific GSC properties, GSCs survive therapy and give rise to new tumour formation and re-initiate the disease. By using SC specific promoters such as, Cox-2, hTERT and mdr, Bauerschmitz et al were able to show a reduction in breast cancer SC population after the treatment with Ad5/3-mdr-Δ24.111 Research on brain specific cancer SCs has shown that tumour-selective oncolytic adenovirus Delta-24-RGD replicates and induces cell death in GSCs. A phase I clinical trial for patients with malignant gliomas is currently underway.112 oHSV has also been used to target GSCs. G47∆ has been tested in combination with a low-dose etoposide and showed increased tumour cell apoptosis and increased survival of mice with etoposide-insensitive intracranial human GSC-derived tumours.113 G47∆ has also been shown to cooperate with temozolomide in killing GSCs through viral manipulation of DNA damage response pathways in preclinical models.114 A modified oHSV, MG18L, containing a Us3 deletion and an inactivating LacZ insertion in UL39, replicates in GSCs and has antitumour activity in GBM cells in vivo. Furthermore, when MG18L was used in combination with phosphoinositide-3-kinase/Akt inhibitors, increased GSC and glioma apoptosis were observed and survival of GBM-bearing mice was prolonged when compared with treatment with either single therapeutic agent alone.115 Other groups have used OV vectors carrying an exogenous Endo-Angio fusion gene (VAE) to infect and lyse GSCs and have shown the significance of this modality in vitro.116 Moreover, GSCs have been shown to overexpress ATP-binding cassette (ABC) transporters, especially ABCG2 that can pump out active prodrugs and resist suicide gene therapy.117 Combining an ABCG2 blocker, such as gefitinib, with other suicide gene therapy vectors may provide an opportunity to further target GSCs and improve the therapeutic efficacy of antiglioma suicide gene therapy systems.117
Preclinical animal model
The therapeutic efficacy of most antiglioma gene therapeutic approaches is commonly evaluated in immunocompromised animal models using xenogeneic cells for tumour implantation with only a short interval of time between engraftment and treatment. The circumstances in human GBM do not closely mimic those in animal models as tumour initiation is usually sporadic and clinical symptoms can be observed months to years after initial establishment, resulting in increased heterogeneity. Thus, for the successful investigation of gene therapies, it is essential to build good animal models that are both reliable and representative of human glioma. To date, many models exist including: implantation of rodent glioma cells into immunocompetent rodents, implantation of human GBM into immunocompromised nude mice and endogenous brain tumour animal models.118 These models have been used due to their high level of reproducibility and characteristics that accurately recapitulate the tumour microenvironment, heterogeneity, growth pattern, histopathology and antitumour immune response represented in human GBM.33 Although these models are widely used and have generated vast amounts of data to lead to the development of novel gene therapies, the failure of the studied therapies transition into the clinic can be partially attributed to a need for a superior glioma model. As one of the possible options, the spontaneous GBM model in the brachycephalic canine has been reported.119 Canine GBM is highly invasive and mimics human GBM characteristics such as necrosis with pseudopalizading, neovascularisation and endothelial proliferation.5 Stoica et al have reported that GSCs are present in dog GBM and have a high capacity for self-renewal, proliferation and differentiation similar to human GBM.96 The most important aspect of the canine model is its comparable brain size to the human brain. This characteristic is essential for a good preclinical model in order to precisely assess such pharmacokinetic properties as toxicity, dosage, side effects, as well as measure delivery strategies. For example, NSCs have been shown to deliver gene therapies to targeted tumour sites beyond the primary tumour in small animal models. But can NSCs withstand the test of distance and deliver to metastatic sites far away from the site of injection in a human brain? The failures of gene therapy can be undoubtedly linked to the inaccessibility to animal models that recapitulate human GBM and therefore answer prudent questions about an antiglioma gene therapy before its translation into clinical trials. It is essential to collaborate with veterinarian institutions that receive glioma bearing canines and cancer gene therapy laboratories with a need for this model, in order to bring antiglioma gene therapy closer to achieving clinical relevance.
Conclusions and future direction
Although antiglioma gene therapies have demonstrated promising efficacy in preclinical glioma models with favourable safety profiles in phase I clinical trials, they have ultimately failed to provide significant benefits in both phase II and III clinical trials. Since gene therapy has demonstrated great promise in the preclinical setting, we must accept the initial discouraging outcomes of clinical trials with a grain of salt. A majority of antiglioma phase I clinical trials have been conducted on patients with advanced stage cancer, and this may contribute to their low success rate. In order to adequately judge efficacy, clinical trials need to be conducted on patients with earlier stages of cancer. Furthermore, many phase I clinical trials are designed to determine the safety profile of a treatment modality and not clinical efficacy. Others have suggested that the failure of phase III clinical trials can be attributed to the lack of ‘preclinical robustness,’ a term coined to describe the need for more stringent experimental protocols that address whether a therapy will be well translated into the clinical setting.120 As the field of gene therapy moves forward, it is vital that we modify current gene therapy approaches and adopt new ways to overcome the formidable obstacles GBM has presented. A growing level of attention has been given to therapeutic synergies. Antiglioma gene therapies such as OVs and genetically modified SCs have the potential to cooperate with standard modes of treatment.121 An optimal combination therapy would include a well-designed strategy that uses multiple therapies to target heterogeneous GBM.91 Multiple treatment modalities will have the power to target different parts of the tumour such as the tumour bulk or GSCs, which address the importance of strategically targeting tumour heterogeneity. The synergistic advantages between multiple therapies need to be further evaluated to attain optimal results. Given the highly variable and evolving nature of GBM, advancements in non-invasive imaging protocols and cancer genomics will allow neuro-oncologists to acquire information such as the molecular, cellular, genetic and epigenetic makeup of a specific tumour. This information will provide the clinician with the powerful tools to continually provide personalised gene therapy treatment protocols that can be adjusted based on specific and real-time information gathered on an individual basis. Although the road ahead is challenging, if we can overcome the obstacles and ameliorate current antiglioma gene therapies, one day it may be possible that gene therapy can be used as the standard of care for GBM patients.
Funding Research by the authors was supported by the NCI (R01CA122930, R01CA138587), the National Institute of Neurological Disorders and Stroke (U01NS069997) and the American Cancer Society (RSG-07-276-01-MGO).
Competing interests None.
Provenance and peer review Commissioned; externally peer reviewed.